Cullinan Therapeutics, Inc. (CGEM): Depreciation & Amortization
$311.0K
Year ended 2025-12-31
$316.0K
Trailing 12 months to 2026-06-30
+49.5%
3-year compound annual growth
+38.1%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $311.0K | +1.6% | 2026-03-10, From 2025-01-01 |
| 2024-12-31 | $306.0K | -1.3% | 2026-03-10, From 2024-01-01 |
| 2023-12-31 | $310.0K | +233.3% | 2025-02-27, From 2023-01-01 |
| 2022-12-31 | $93.0K | +75.5% | 2024-03-14, From 2022-01-01 |
| 2021-12-31 | $53.0K | -14.5% | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | $62.0K | n/a | 2022-03-17, From 2020-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | 2025-12-31 | $311.0K | +1.6% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $15.62M | -3.7% |
| Allogene Therapeutics, Inc. (ALLO) | 2025-12-31 | $12.36M | -9.4% |
| Vericel Corp (VCEL) | 2025-12-31 | $11.54M | +109.7% |
| Scholar Rock Holding Corp (SRRK) | 2025-12-31 | $1.66M | -14.4% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $15.53M | -11.6% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $16.00M | -8.3% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $1.39M | +11.5% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $4.62M | +14.3% |
Compare CGEM, RGNX, ALLO, VCEL side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗